MedTrace Logo

To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy

NCT03533959 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2018-05-30

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy of alirocumab for in-stent neoatherosclerosis by using optical coherence tomography, in comparison with standard statin therapy.

Conditions

  • Coronary Artery Disease Progression

Interventions

DRUG

Alirocumab

the administration of Alirocumab at least 75mg every 2 weeks

Sponsors & Collaborators

  • Kobe University

    lead INDUSTRY

Principal Investigators

  • Hiromasa Otake, M.D., Ph.D · Kobe University Graduate School of Medicine

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-18
Primary Completion
2020-12-31
Completion
2025-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03533959 on ClinicalTrials.gov